Xilio Therapeutics
Xilio Therapeutics' revenue rose 589.9% to $44 million in fiscal 2025. Its operating margin was −95.9%, up from −955.0% a year earlier. Free cash flow was −$6 million. The diluted share count rose 118.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Xilio Therapeutics lost money in fiscal 2025: a net loss of $35 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 198 | 120 | 45 | 55 | 138 |
| Debt incl. finance leases | — | 10 | — | — | — |
| Net debt (negative means net cash) | — | −110 | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 0.1x | — | — | — |
| Interest coverage | −152.5x | −160.6x | −138.1x | −977.1x | — |
| Current ratio | 15.8x | 5.9x | 3.0x | 2.2x | 2.6x |
| Quick ratio | 15.8x | 5.9x | 3.0x | 2.2x | 2.6x |
Cash flow
Projections
Project Xilio Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $43,950 of Xilio Therapeutics shares on the open market, and 2 insiders sold $5,668, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 2026 | James Samuel ShannonDirector | Bought | 5,000 | $8.79 | $43,950 | Form 4 |
| Jan 2, 2026 | Christopher James FrankenfieldChief Financial Officer | Sold plan | 7,030 | $0.64 | $4,499 | Form 4 |
| Jan 2, 2026 | Kevin M. BrennanSVP, Finance and Accounting | Sold plan | 1,826 | $0.64 | $1,169 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | 577.3% |
| Altman Z'' | −21.08 | −19.94 | −6.58 |
| Accruals ratio | −7.8% | −60.4% | −26.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Pass | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | Pass |
| F-score | — | — | — |
Compare
Put Xilio Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Xilio Therapeutics | FY25 | 589.9% | −95.9% | −12.6% | — | — | — | |
| Aquestive Therapeutics | FY25 | −22.6% | −159.5% | −119.0% | — | — | 2 | Compare |
| Cumberland Pharmaceuticals | FY25 | 17.6% | −6.3% | 10.9% | — | — | — | Compare |
| Lexicon Pharmaceuticals | FY25 | 60.2% | −98.2% | −136.2% | −105.0% | — | 4 | Compare |
| BGM Group | FY25 | 51.1% | −33.2% | −10.4% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | 6 | 44 |
| Revenue growth | — | — | — | — | — | 589.9% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 44 | 51 | 59 | 52 | 41 | 56 |
| Operating income | −55 | −75 | −89 | −79 | −61 | −42 |
| Net income | −55 | −76 | −88 | −76 | −58 | −35 |
| Diluted EPS (US$) | −105.42 | −13.52 | −3.22 | −2.78 | −15.24 | −4.19 |
| Diluted shares (millions) | 0 | 6 | 27 | 28 | 4 | 8 |
| Cash flow | ||||||
| Cash from operations | −36 | −81 | −76 | −69 | −18 | −5 |
| Capital expenditure | 2 | 1 | 2 | 0 | 0 | 0 |
| Free cash flow | −38 | −82 | −78 | −69 | −18 | −6 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 5 | 8 | 7 | 6 | 7 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 19 | 198 | 120 | 45 | 55 | 138 |
| Debt incl. finance leases | 10 | — | 10 | — | — | — |
| Total assets | 36 | 218 | 139 | 61 | 71 | 155 |
| Total liabilities | 42 | 33 | 34 | 24 | 54 | 119 |
| Shareholders' equity | −83 | 185 | 106 | 37 | 18 | 35 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | −955.0% | −95.9% |
| Net margin | — | — | — | — | −918.0% | −80.0% |
| Free cash flow margin | — | — | — | — | −290.3% | −12.6% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | 577.3% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −148.4% | −60.6% | −107.2% | −214.0% | −132.5% |
| Return on assets | — | −59.6% | −49.4% | −76.4% | −88.2% | −31.0% |
| Net debt to EBITDA | — | — | — | — | — | — |